Objectives: The aim of this study was to evaluate the diagnostic significance of high-risk human papillomavirus (hrHPV) testing for managing women with atypical glandular cells (AGC) and to explore the distribution of hrHPV genotypes. Methods: We analyzed cytologic and histopathologic diagnoses in patients referred to our institution due to AGC or atypical squamous cells of undetermined significance (ASC-US). All patients underwent hrHPV testing and genotyping, and positive (PPV) and negative predictive values (NPV) for cervical intraepithelial neoplasia (CIN) 2 or worse [CIN2+/adenocarcinoma in situ (AIS)+] were calculated. Results: Among 41 cases previously diagnosed with AGC, 22 (53%) were classified as CIN2+ (2 squamous cell carcinomas), whereas only 2 were AIS or adenocarcinoma. Twenty-seven (65.8%) cases in the AGC group were hrHPV positive. The most frequent genotypes in both the ASC-US and AGC groups were HPV16 and HPV52. The PPV of hrHPV testing for CIN2+/AIS+ was significantly higher in the AGC than in the ASC-US group (74.1 vs. 35.0%; p = 0.0005). The NPV for CIN2+/AIS+ was significantly lower in the AGC than in the ASC-US group (74.4 vs. 100%; p = 0.0441). Conclusion: In patients with AGC, both glandular and squamous lesions must be monitored. hrHPV testing is useful for detecting CIN2+/AIS+ in AGC.

1.
Solomon D, Nayar R: The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria and Explanatory Notes, ed 2. New York, Springer, 2003, p 128.
2.
Kinney W, Sawaya GF, Sung HY, Kearney KA, Miller M, Hiatt RA: Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the cervix diagnosed as a consequence of cytologic screening. Acta Cytol 2003; 47: 167–171.
3.
Syrjanen K: Is improved detection of adenocarcinoma in situ a key to reducing the incidence of endocervical adenocarcinoma? Acta Cytol 2004; 48: 591–594.
4.
Mitchell H, Hocking J, Saville M: Cervical cytology screening of women diagnosed with adenocarcinoma in situ of the cervix: a case control study. Acta Cytol 2004; 48: 595–600.
5.
Rabelo-Santos SH, Derchain SF, do Amaral Westin MC, Angelo-Andrade LA, Sarian LO, Oliveira ER, Morais SS, Zeferino LC: Endocervical glandular cell abnormalities in conventional cervical smears: evaluation of the performance of cytomorphological criteria and HPV testing in predicting neoplasia. Cytopathology 2008; 19: 34–43.
6.
Westin MC, Derchain SF, Rabelo-Santos SH, Angelo-Andrade LA, Sarian LO, Oliveira E, Zeferino LC: Atypical glandular cells and adenocarcinoma in situ according to the Bethesda 2001 classification: cytohistological correlation and clinical implications. Eur J Obstet Gynecol Reprod Biol 2008; 139: 79–85.
7.
Kim SS, Suh DS, Kim KH, Yoon MS, Choi KU: Clinicopathological significance of atypical glandular cells on Pap smear. Obstet Gynecol Sci 2013; 56: 76–78.
8.
Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11: 201–222.
9.
Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M Solomon D, Wentzensen N, Lawson HW; 2012 ASCCP Consensus Guidelines Conference: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17(5 suppl 1):S1–S27.
10.
Wright TC Jr, Lorincz AT, Ferris DG, Rickart RM, Ferenczy A, Mielzynska I, Borgatta L: Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998; 178: 962–966.
11.
Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA: Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281: 1605–1610.
12.
Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G: Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000; 95: 821–827.
13.
Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS: High-risk HPV DNA detection by Hybrid Capture II: an adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age. J Reprod Med 2000; 45: 345–350.
14.
Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM Jr: Prediction of cervical intraepithelial neoplasia grade 2–3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol 2000; 96: 410–416.
15.
Solomon D, Schiffman M, Tarone R; ALTS Study group: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 293–299.
16.
The ASCUS-LSIL Triage Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383–1392.
17.
Verdoodt F, Jiang X, Williams M, Schnatz PF, Arbyn M: High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis. Int J Cancer 2016; 138: 303–310.
18.
Shoji T, Takatori E, Takeuchi S, Yoshizaki A, Uesugi N, Sugai T, Sugiyama T: Clinical significance of atypical glandular cells in the Bethesda system 2001: a comparison with the histopathological diagnosis of surgically resected specimens. Cancer Invest 2014; 32: 105–109.
19.
Schiffman M, Vaughan LM, Raine-Bennett TR, Castle PE, Katki HA, Gage JC, Fetterman B, Befano B, Wentzensen N: A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol Oncol 2015; 138: 573–578.
20.
Namugenyi SB, Balsan MJ, Glick SN, Jordan JA: Prevalence and genotype distribution of human papillomavirus in cytology specimens containing atypical glandular cells: a case-control study. J Clin Virol 2013; 58: 432–436.
21.
Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Darcy KM, Carter R, Levine L, Spirtos NM, Susumu N, Fujiwara K, Walker JL, Hatae M, Stanbridge EJ: Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) study. Br J Cancer 2011; 104: 353–360.
22.
Zeferino LC, Rabelo-Santos SH, Villa LL, Sa-rian LO, Costa MC, Westin MC, Angelo-Andrade LA, Derchain S: Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC). Eur J Obstet Gynecol Reprod Biol 2011; 159: 160–164.
23.
Holl K, Nowakowski AM, Powell N, McCluggage WG, Pirog EC, De Souza SC, Tjalma WA, Rosenlund M, Fiander A, Castro Sánchez M, Damaskou V, Joura EA, Kirschner B, Koiss R, O’Leary J, Quint W, Reich O, Torné A, Wells M, Rob L, Kolomiets L, Molijn A, Savicheva A, Shipitsyna E, Rosillon D, Jenkins D: Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: results from a European multinational epidemiological study. Int J Cancer 2015; 137: 2858–2868.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.